このエントリーをはてなブックマークに追加
ID 31183
本文ファイル
著者
Ochiai, Mariko
Takasugi, Norihisa
Kiribayashi, Kei
Kawai, Toru
Usui, Koji
Shigemoto, Kenichiro
Hamaguchi, Naoki
Yorioka, Noriaki
キーワード
Vitamin K2
Bone metabolism markers
Intact parathyroid hormone
Hemodialysis
NDC
医学
抄録(英)
Background: A low level of intact parathyroid hormone (PTH) is an indicator of adynamic bone disease in hemodialysis patients, and is associated with a significant increase of all-cause mortality. Thus, effective treatment for adynamic bone disease is required. We previously investigated the effect of vitamin K2 on adynamic bone disease. In this study, we assessed the efficacy of oral vitamin K2 in a controlled trial.

Methods: Forty hemodialysis patients with low intact PTH levels (<100 pg/ml) were randomly divided into two groups, which were a vitamin K2 group receiving oral menatetrenone (45 mg/day) for 1 year and a control group without vitamin K2. Venous blood samples were collected at baseline and during the study for measurement of bone metabolism parameters.

Results: Thirty-three patients completed follow-up. There was a significant increase of the serum intact osteocalcin level after 1 month of vitamin K2 administration. Serum levels of intact PTH, bone alkaline phosphatase, and cross-linked N-terminal telopeptide of type I collagen increased significantly after 12 months in the vitamin K2 group. The serum osteoprotegerin level was decreased after 12 months in the vitamin K2 group, but the change was not significant.

Conclusion: Vitamin K2 therapy improves bone remodeling in hemodialysis patients with a low intact PTH level.
掲載誌名
Nephron Clinical Practice
117巻
1号
開始ページ
c15
終了ページ
c19
出版年月日
2011
出版者
Karger
ISSN
1660-2110
出版者DOI
言語
英語
NII資源タイプ
学術雑誌論文
広大資料タイプ
学術雑誌論文
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
author
権利情報
Copyright (c) 2010 S. Karger AG, Basel
関連情報URL
部局名
医歯薬学総合研究科